Glucagon nasal powder: Preliminary Phase II/III data

Preliminary data from a U.S. Phase II/III trial in 48 Type I diabetics ages 4-16 with severe hypoglycemia showed that 2 and 3 mg doses of glucagon nasal powder were well tolerated and led to an increa...